Latest ABBV news

Prediction: Here's What $10,000 Invested in AbbVie Stock With Dividends Reinvested Could Be Worth in a Decade

The Motley Fool · Thu, 24 Sep 2026 00:30:00 -0400

AbbVie has increased its dividend for 53 consecutive years. It has a strong pipeline and is willing to spend heavily on R&D.

AbbVie's Rinvoq Wins EU Approval in Juvenile Idiopathic Arthritis

Zacks Investment Research · Tue, 22 Sep 2026 13:21:13 -0400

ABBV's Rinvoq secures EU approval for pJIA in children, expanding ABBV's reach as clinical data show sustained improvements in disease activity.

Allergan Aesthetics Debuts AA Signature™ in the United States with SKIN360, Its First Multimodal Consultation Approach

PRNewsWire · Tue, 22 Sep 2026 08:00:00 -0400

AA Signature: SKIN360 marks the first in a series of assessment protocols addressing patients' evolving aesthetic goals. The program includes provider education and resources to support 96% of patients who are interested in a comprehensive aesthetic consultation.

AbbVie vs. Pfizer: Which Dividend Stock Is the Better Buy in September?

The Motley Fool · Tue, 22 Sep 2026 06:05:00 -0400

Dividend payments offer you security in difficult markets -- and extra growth in better times. These pharma companies offer dividend yields that beat the dividend yield of the S&P 500.

3 Dividend Stocks to Buy Before September Ends and Hold Forever

24/7 Wall Street · Tue, 22 Sep 2026 06:00:26 -0400

With the third quarter closing out, income investors have a narrow window to lock in three cash-generative blue chips before Q3 earnings reset expectations. The shared hook: recession-resilient franchises, multi-decade dividend histories, and reaffirmed or raised 2026 guidance.

AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic Arthritis

PRNewsWire · Tue, 22 Sep 2026 02:00:00 -0400

RINVOQ is now approved in the European Union for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients two years of age and older who have responded inadequately to, or who are intolerant to, one or more DMARDs 1 Approval was based on the open-label Phase 1 SELECT-YOUTH study and data from adults with rheumatoid arthritis 1,2 A new oral solution of RINVOQ was approved for use in patients with pJIA 1 RINVOQ is currently approved in the European Union for 11 indications across various immune-mediated, inflammatory diseases 1 NORTH CHICAGO, Ill., Sept. 22, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Commission (EC) has approved RINVOQ® (upadacitinib; 15 mg tablet and weight-based 1 mg/mL oral solution) for the treatment of active polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [RF+] or negative [RF-], extended oligoarticular), in patients two years of age and older who have responded inadequately to, or who are intolerant to, one or more disease-modifying anti-rheumatic drugs (DMARDs).

AbbVie and Iambic Announce Collaboration to Accelerate AI-driven Drug Discovery

PRNewsWire · Mon, 21 Sep 2026 08:00:00 -0400

Multi-year partnership applies Iambic's AI platform to speed up small molecule drug discovery in immunology, neuroscience and oncology Companies to pursue programs with both first-in-class and best-in-class potential, combining Iambic's molecular superintelligence platform with AbbVie's therapeutic area expertise NORTH CHICAGO, Ill. and SAN DIEGO, Sept.

Market information is provided for research and visualization and is not investment advice.